International Journal of Molecular Sciences (Nov 2022)

Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer

  • Kosuke Imamura,
  • Yusuke Tomita,
  • Ryo Sato,
  • Tokunori Ikeda,
  • Shinji Iyama,
  • Takayuki Jodai,
  • Misako Takahashi,
  • Akira Takaki,
  • Kimitaka Akaike,
  • Shohei Hamada,
  • Shinya Sakata,
  • Koichi Saruwatari,
  • Sho Saeki,
  • Koei Ikeda,
  • Makoto Suzuki,
  • Takuro Sakagami

DOI
https://doi.org/10.3390/ijms232213723
Journal volume & issue
Vol. 23, no. 22
p. 13723

Abstract

Read online

T cells express an actin-binding protein, drebrin, which is recruited to the contact site between the T cells and antigen-presenting cells during the formation of immunological synapses. However, little is known about the clinical implications of drebrin-expressing, tumor-infiltrating lymphocytes (TILs). To address this issue, we evaluated 34 surgical specimens of pathological stage I–IIIA squamous cell lung cancer. The immune context of primary tumors was investigated using fluorescent multiplex immunohistochemistry. The high-speed scanning of whole-slide images was performed, and the tissue localization of TILs in the tumor cell nest and surrounding stroma was automatically profiled and quantified. Drebrin-expressing T cells were characterized using drebrin+ T cells induced in vitro and publicly available single-cell RNA sequence (scRNA-seq) database. Survival analysis using the propensity scores revealed that a high infiltration of drebrin+ TILs within the tumor cell nest was independently associated with short relapse-free survival and overall survival. Drebrin+ T cells induced in vitro co-expressed multiple exhaustion-associated molecules. The scRNA-seq analyses confirmed that the exhausted tumor-infiltrating CD8+ T cells specifically expressed drebrin. Our study suggests that drebrin-expressing T cells present an exhausted phenotype and that tumor-infiltrating drebrin+ T cells affect clinical outcomes in patients with resectable squamous cell lung cancer.

Keywords